Related Experiment Video
Updated: Mar 3, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Dongmei Zhang1,2,3, Gao Zhang4,5, Xiaowen Hu2
1Department of Gynecology and Obstetrics, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Abstract:
RAS and its downstream cascades transmit cellular signals, resulting in increased transcription of genes involved in cell growth and division. Protein-coding gene targets of RAS signaling have been characterized extensively, but long noncoding RNAs (lncRNA) regulated by these processes have not. Using a custom-designed lncRNA microarray, we identified the lncRNA Orilnc1 as a genetic target of RAS that is critical for RAS oncogenicity. Orilnc1 expression was regulated by RAS-RAF-MEK-ERK signaling via the transcription factor AP1. Orilnc1 was highly expressed in BRAF-mutant cancers, such as melanoma. Silencing of Orilnc1 blocked tumor cell proliferation and growth in vitro and in vivo In addition, Orilnc1 blockade reduced expression of cyclin E1 and induced G1-S cell-cycle arrest in tumor cells. Taken together, our results identify Orilnc1 as a novel, nonprotein mediator of RAS/RAF activation that may serve as a therapeutic target in RAS/RAF-driven cancers. Cancer Res; 77(14); 3745-57. ©2017 AACR.
Insights
Researchers discovered a new long noncoding RNA, Orilnc1, that drives RAS oncogenicity. Silencing Orilnc1 halts tumor growth and may offer a new therapeutic target for RAS/RAF-driven cancers.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- RAS signaling pathways regulate cell growth and division.
- While protein-coding targets are known, RAS-regulated long noncoding RNAs (lncRNAs) are less understood.
Purpose of the Study:
- Identify novel lncRNAs regulated by RAS signaling.
- Investigate the role of identified lncRNAs in RAS-driven oncogenesis.
Main Methods:
- Utilized a custom lncRNA microarray to screen for RAS-regulated lncRNAs.
- Investigated the regulatory mechanism of Orilnc1 expression via RAS-RAF-MEK-ERK signaling and AP1.
- Assessed the functional impact of Orilnc1 silencing on tumor cell proliferation and cell cycle progression in vitro and in vivo.
Main Results:
- Identified Orilnc1 as a novel genetic target of RAS signaling.
- Demonstrated that Orilnc1 expression is regulated by the RAS-RAF-MEK-ERK pathway via AP1.
- Observed high Orilnc1 expression in BRAF-mutant cancers like melanoma.
- Showed that Orilnc1 silencing inhibits tumor cell proliferation and growth.
- Found that Orilnc1 blockade reduces cyclin E1 expression and induces G1-S cell-cycle arrest.
Conclusions:
- Orilnc1 is a critical mediator of RAS oncogenicity.
- Orilnc1 functions as a nonprotein effector of RAS/RAF activation.
- Orilnc1 represents a potential therapeutic target for cancers driven by RAS/RAF mutations.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
The Ras Gene
Ras is a...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
MicroRNAs
MicroRNAs
